Guggenheim’s Rohit Vanjani is reassured from the sidelines on TEVA’s fremanezumab’s prospects to clear an FDA not despite supply plant’s Warning Letter.
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) announced that it successfully priced the offering of $4.5 billion of its previously announced senior notes.
This analyst isn’t ready to get bullish on TEVA. Here’s why.
BTIG’s Tim Chiang is out with a bearish case against Teva after last week’s less-than-stellar 2018 guidance reveal.
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) today announced the US launch of its generic equivalents to Valeant’s (NYSE:VRX) 30-year-old drug, Syprine (trientine hydrochloride), used …
As Wall Street scrambles away from Teva after a sharp guidance miss for 2018, Oppenheimer’s Derek Archila shares his two (cautious) cents.
Generics price erosion; the ghost of debt maturation- BTIG’s Tim Chiang sees too many risks to hope for Teva’s recovery anymore.
Though Guggenheim’s Rohit Vanjani is not surprised by Teva’s amendment of financial leverage covenants, he sees this as a “watch” item.
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) announced today it has completed the sale of a portfolio of products within its global women’s health …
BTIG’s Tim Chiang cautions that Momenta’s generic 40mg Copaxone is not the only rival coming for Teva.